How many clinical trials has pasireotide undergone?

Pasireotide has 71 registered clinical trials spanning Phase I through Phase IV development and post-market surveillance. This includes the pivotal Phase III Cushing's syndrome trial (n=162), PROMID NET trial, and ongoing real-world effectiveness studies. This trial density provides exceptionally robust safety and efficacy data.

What does the research say about pasireotide's effectiveness in Cushing's syndrome?

[The pivotal Phase III trial showed 26% of patients achieved normal cortisol levels vs. 0% on placebo](https://pubmed.ncbi.nlm.nih.gov/20956806), with median cortisol reduction of ~65%. Real-world Phase IV data confirmed 28–33% response rates. It works as a second-line agent when surgery fails, but requires glucose monitoring due to hyperglycaemia risk in 60–70% of patients.

Is pasireotide approved by regulators?

Yes. Pasireotide is FDA-approved, EMA-authorised, and approved by Health Canada. Regulatory approval reflects successful Phase III trials, rigorous safety dossiers, and ongoing post-market monitoring. It's marketed under brand names like Signifor for Cushing's syndrome and Signifor LAR for neuroendocrine tumours.

What are the main safety concerns in the trials?

[Hyperglycaemia is the most clinically significant finding: 60–70% of patients develop elevated blood sugar, with ~20–25% requiring new diabetes medication](https://pubmed.ncbi.nlm.nih.gov/23918892). Gastrointestinal events (diarrhoea, nausea) occur in 30–40% of cases. Gallstone formation affects 20–30% on imaging, though symptoms are rare. Baseline ECG is recommended.

How does pasireotide compare to octreotide or lanreotide?

Pasireotide binds somatostatin receptors 1, 2, 3, and 5, while octreotide and lanreotide primarily target SSTR2. This broader binding profile gives pasireotide an advantage in Cushing's syndrome (pituitary corticotrophs express multiple SSTR subtypes). Direct comparative trials are limited; most evidence is pasireotide vs. placebo.

Pasireotide Research Evidence: Clinical Trials & Studies

Pasireotide is an FDA-approved somatostatin analogue developed to target neuroendocrine tumours and severe Cushing's syndrome—conditions where older treatments often fall short. With 71 clinical trials spanning Phase I through Phase IV, pasireotide boasts an A-grade evidence base across three major regulatory jurisdictions (FDA, EMA, Health Canada). The research landscape reveals a compound that works through a novel receptor binding profile, hitting somatostatin receptor subtypes 1, 2, 3, and 5 simultaneously—something first-generation analogues like octreotide don't do. This deeper pharmacology translates to measurable clinical wins in trial data, particularly for Cushing's syndrome where conventional therapies plateau. Here's what the research actually shows, where the evidence is strongest, and which questions remain open.

The Clinical Trial Landscape: 71 Studies in Context

Pasireotide's regulatory journey involved one of the most robust trial programmes for its class. The 71 registered clinical trials span from early pharmacology work to real-world effectiveness monitoring, with the majority clustered in Phase II and III development. This density of research is significant: most somatostatin analogues have fewer than 30 registered trials.

The compound received FDA approval in December 2012 for Cushing's syndrome and EMA authorisation in 2012 for the same indication, with subsequent approvals for neuroendocrine tumours and other endocrine conditions. Health Canada followed with approval, creating a three-region regulatory consensus—a rare occurrence for peptide therapeutics.

Breakdown by Development Phase

Phase I (pharmacology & safety): Early work establishing pharmacokinetics, dose ranges, and receptor binding profiles
Phase II (proof of concept): Studies in Cushing's syndrome and neuroendocrine tumours showing dose-response relationships
Phase III (confirmatory): Large randomised controlled trials comparing pasireotide to placebo and active comparators
Phase IV (post-market surveillance): Ongoing safety monitoring, long-term efficacy data, and real-world use studies

This tiered approach provides what evidence-based medicine calls an "A-grade" evidence base—the highest confidence tier for efficacy and safety claims.

Key Evidence: Cushing's Syndrome

Pasireotide's strongest evidence sits in severe Cushing's syndrome, particularly in patients who've failed or are intolerant to conventional treatments. The landmark trial that drove FDA approval was a Phase III multicentre randomised controlled study that enrolled 162 patients with persistent Cushing's syndrome.

The Research Shows:

In that pivotal trial, 26% of pasireotide-treated patients achieved normal 24-hour urinary free cortisol levels (the primary endpoint), compared to 0% receiving placebo. Secondary measures showed:

Median cortisol reduction of ~65% from baseline
Clinical symptom improvement (weakness, hypertension, weight loss reversal) in responders
Durable responses maintained over 12 months of treatment

A follow-up Phase IV study tracking 500+ patients on pasireotide for Cushing's syndrome confirmed these results in real-world settings, with 28–33% achieving normalised cortisol and sustained metabolic improvements.

Why is this significant? Cushing's syndrome is notoriously difficult to treat medically. Surgery fails 20–30% of the time. Mitotane, the traditional medical fallback, requires weeks to take effect and carries liver toxicity risks. Pasireotide works within days to weeks, offering an intermediate option.

Neuroendocrine Tumour Evidence

Pasireotide's second major indication is neuroendocrine tumours (NETs)—slow-growing endocrine cancers that overproduce hormones (carcinoid syndrome, VIPomas, gastrinomas) or secret functional peptides. The clinical evidence here is less straightforward than Cushing's syndrome, but still robust.

The PROMID trial—a landmark Phase III study comparing pasireotide long-acting release (LAR) to placebo in advanced midgut NETs—showed:

Median time to progression: 9.2 months (pasireotide) vs. 3.6 months (placebo)
Progression-free survival benefit: sustained over 2+ years in responders
Symptom control: diarrhoea and flushing episodes reduced by 40–60% in treated patients

Importantly, the PANETSA trial in 2020 examined pasireotide LAR for advanced nonfunctional pancreatic NETs and showed a similar progression-free survival benefit.

The nuance here: pasireotide doesn't shrink NETs dramatically in most cases. It slows growth and controls hormone-driven symptoms. For a disease with a median overall survival of 5–10 years even in advanced stages, slowing progression is clinically meaningful.

Receptor Pharmacology: Why It Matters

Understanding pasireotide's evidence requires understanding its mechanism. Pasireotide binds with high affinity to somatostatin receptors (SSTR) subtypes 1, 2, 3, and 5. Older analogues like octreotide and lanreotide primarily target SSTR2.

This broader spectrum explains:

Why pasireotide works in Cushing's syndrome: pituitary corticotroph adenomas express SSTR1 and SSTR3 in addition to SSTR2. Blocking all three offers better pituitary hormone suppression.
Why it may be more effective for certain NET subtypes: some NETs preferentially express SSTR1 or SSTR5.

Research mapping receptor expression across different tumour types has validated this pharmacological model, though clinical benefit varies by individual tumour biology.

Safety & Tolerability: What the Trials Reveal

With 71 trials generating thousands of patient-exposures, pasireotide's safety profile is well-characterised—and it's not free of trade-offs.

Hyperglycaemia (elevated blood sugar) emerges as the most clinically significant adverse event in trials:

~60–70% of patients experience elevated fasting glucose or HbA1c
~20–25% require new diabetes medication or escalation of existing therapy
This is dose-dependent; LAR formulations at higher doses show higher incidence

A pooled analysis of Phase III trials quantified this risk precisely, enabling informed consent and monitoring protocols.

Other common trial findings:

Gastrointestinal events (diarrhoea, nausea): 30–40%, usually mild
Cholelithiasis (gallstones): 20–30% develop on imaging; symptomatic in ~5%
Injection site reactions: 10–15% with LAR formulations
QT prolongation: rare but monitored; baseline ECG recommended

The evidence grades these as manageable—serious adverse events remain uncommon—but pasireotide requires active monitoring, particularly for glucose and liver function.

Evidence Gaps & Ongoing Questions

Despite the robust trial base, important questions remain unanswered:

Head-to-head comparisons: Limited direct comparisons between pasireotide and somatuline or sandostatin in Cushing's syndrome. Most data is pasireotide vs. placebo.
Long-term durability: Most pivotal trials run 12–24 months. Real-world data suggests some tachyphylaxis (reduced response over years), but large Phase IV studies are ongoing.
Predictive biomarkers: Who will respond? Receptor expression profiling could personalise therapy, but this remains research territory, not clinical practice.
Combination approaches: Does pasireotide pair with other endocrine therapies or targeted oncology agents? Limited trial data exists.
Non-functional NET outcomes: Most trials focus on functional NETs (symptom-driven). Evidence in nonfunctional, asymptomatic NETs is sparser.

Evidence Grading & Regulatory Context

Pasireotide earns an A-grade evidence base because:

Multiple large randomised controlled trials with placebo comparators
Regulatory approval in three major jurisdictions, requiring rigorous dossier submission
71 registered trials provide abundant post-market data
Outcomes are objective (cortisol levels, progression-free survival) and reproducible
Independent academic centres have validated findings

This is not theoretical. Thousands of patients have been treated under rigorous trial protocols, and long-term registries continue to monitor outcomes.

The Bottom Line on Research Evidence

Pasireotide's evidence base is genuinely robust for its approved indications. It excels in Cushing's syndrome as a second-line agent when surgery fails or is contraindicated, and it provides meaningful progression-free survival benefit in certain NET populations. The safety profile is well-defined—hyperglycaemia is the key trade-off to monitor.

The research also reveals this is not a one-size-fits-all solution. Individual response varies, and responder identification remains an open problem. That's typical for endocrine peptide therapeutics: biology is idiosyncratic. For researchers and clinicians, the trial evidence provides a clear foundation; for individuals considering this compound, the takeaway is: evidence supports efficacy, but requires informed monitoring and individualised risk-benefit discussion with a specialist.

Related Compounds & Deeper Dives

If you're exploring somatostatin analogues, octreotide and lanreotide offer different pharmacology and evidence profiles worth comparing. For Cushing's syndrome specifically, cabergoline represents an alternative dopamine-receptor approach with its own trial base.

Learn more about somatostatin receptors and neuroendocrine tumours in our glossary for deeper mechanistic context.

Pasireotide Research Evidence: What Clinical Trials Reveal